In part 2 of the highlights from day 1 of the EHA/EBMT CAR-T cell meeting, we take a look at some of the emerging science discussed during some of the sessions and how the research might help drive novel and innovative approaches forward in the future.

It can be scary jumping into the unknown!

We’ve heard much about all the phase 3 clinical trials in lymphomas and multiple myeloma of late, yet what about new research which is helping to inform and improve performance of new CAR constructs?

In this latest discussion, we highlight some of the promising scientific concepts, which are emerging and could end up being incorporated into new CAR-T cell therapies down the road in order to address and tackle some of the current weaknesses…

BSB subscribers can read our latest cancer conference coverage and commentary – you can either log-in or click to access.

This content is restricted to subscribers

Posted by